What's in Dutch Colorectal Cancer Group's pipeline?

Dutch Colorectal Cancer Group has 5 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Dutch Colorectal Cancer Group's portfolio?

Top competitors by shared drug class: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gruppo Oncologico Italia Meridionale, Lee's Pharmaceutical Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dutch-colorectal-cancer-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Dutch Colorectal Cancer Group — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dutch Colorectal Cancer Group pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
capecitabine-irinotecan	capecitabine-irinotecan	phase 3	Topoisomerase I inhibitor and thymidylate synthase inhibitor	Topoisomerase I and thymidylate synthase	Oncology
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)	Oncology
FOLFOX/ FOLFIRI with panitumumab	FOLFOX/ FOLFIRI with panitumumab	phase 3	Chemotherapy combination with EGFR inhibitor	EGFR (panitumumab component)	Oncology
FOLFOX/ FOLFIRI with bevacizumab	FOLFOX/ FOLFIRI with bevacizumab	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)	Oncology
epirubicin+cisplatin+capecitabine	epirubicin+cisplatin+capecitabine	phase 3

Therapeutic area mix

Oncology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · 1 shared drug class
Gruppo Oncologico Italia Meridionale · 1 shared drug class
Lee's Pharmaceutical Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dutch Colorectal Cancer Group:

Cite this brief

Drug Landscape (2026). Dutch Colorectal Cancer Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dutch-colorectal-cancer-group. Accessed 2026-05-17.